BMS-986507 + nivolumab

**BMS-986507 + nivolumab** is an investigational combination therapy composed of BMS-986507 (a monoclonal antibody targeting LAG-3) and nivolumab (a monoclonal antibody targeting PD-1). Both agents function as immune checkpoint inhibitors and are administered together to enhance antitumor immune responses in cancer patients. BMS-986507 blocks the LAG-3 receptor, while nivolumab blocks the PD-1 receptor on T cells, aiming to synergistically restore T-cell activity against tumor cells. This combination is being evaluated for safety, tolerability, and anti-tumor efficacy in advanced solid tumors, including melanoma.